Lymphomas Non-Hodgkin's B-Cell
Oncology
3
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
GS
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Gilead SciencesINT2104
Eureka TherapeuticsET190L1 ARTEMIS™ T cells
Clinical Trials (2)
Total enrollment: 34 patients across 2 trials
A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment
Start: Sep 2024Est. completion: Mar 203134 patients
Phase 1Recruiting
Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma
Start: Apr 2018Est. completion: Jan 2019
Phase 1Terminated
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
4m ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
4m ago
Office Administrator
SystImmune
4m ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
14m ago
Working Student Office Management Support (m/f/d)
Mindpeak
Hamburg
18m ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
18m ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 34 patients
2 companies competing in this space